ホーム>>Signaling Pathways>> Stem Cell>> Wnt/β-catenin>>Wnt agonist 1

Wnt agonist 1 (Synonyms: BML-284)

カタログ番号GC17764

Wnt アゴニスト 1 は、強力で細胞透過性の Wnt シグナル伝達活性化因子です。 Wnt アゴニスト 1 は、TCF 依存性の転写活性を 700 nM の EC50 で誘導します。

Products are for research use only. Not for human use. We do not sell to patients.

Wnt agonist 1 化学構造

Cas No.: 853220-52-7

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$36.00
在庫あり
10mg
$57.00
在庫あり
50mg
$182.00
在庫あり
200mg
$433.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Wnt agonist 1 is a small-molecule agonist of Wnt signaling pathway [1].

The Wnt signaling pathway is an important signal transduction pathway that involved in a variety of physiological and pathological processes by regulating genes involved in cellular adhesion, proliferation, and differentiation [1].

Wnt agonist 1 is a cell-permeable Wnt signaling pathway agonist. Wnt agonist 1 induced b-catenin- and TCF-dependent transcriptional activity in a dose-dependent way with EC50 of 0.7 μM. In Xenopus embryos, treatment with Wnt agonist 1 (10 μM) from developmental stage 10.5 to stage 40 resulted in substantial head defects, such as diminished heads and complete loss of eyes, and reduced eyes and heads. This phenotype is similar to that which results from Wnt over-expression in head specification during early embryonic development.

Reference:
[1].Liu J, Wu X, Mitchell B, et al.  A small-molecule agonist of the Wnt signaling pathway. Angew Chem Int Ed Engl. 2005 Mar 18;44(13):1987-90.

レビュー

Review for Wnt agonist 1

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Wnt agonist 1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.